RxDoctor Payments Data

Brian Viviano, DO

Gastroenterology · Erie, PANPI 1497984512

Payments from drug & device makers

$45,942in general payments, 2019–2025

Across 918 payments — averaging $50.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$22K
  • AbbVie$13K
  • Johnson & Johnson$2K
  • Pfizer$2K
  • Daiichi Sankyo Inc.$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • plus $5K from 27 others

What the payments were for

  • Speaking & faculty fees$28,67062%
  • Travel & lodging$1360%
  • Food & beverage$17,01737%
  • Education$1190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,942 in reported general payments places this provider in the 85th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$23,763
Medicare patients
93
Services billed
180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase12$33,338
LinzessLinaclotide20$15,892
Mesalamine36$9,120
MotegrityPrucalopride Succinate16$8,731
MovantikNaloxegol Oxalate12$7,605
SymproicNaldemedine Tosylate17$7,256
ClenpiqSod Picosulf/Mag Ox/Citric Ac20$3,378
Lubiprostone20$3,174
Pantoprazole Sodium255$2,168
Lansoprazole19$1,819
Colestipol Hcl19$1,495
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates19$1,314
Famotidine96$1,213
Ursodiol11$1,183
Esomeprazole Magnesium69$1,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$13,063$49,23032 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,176$8,73116 claims
Redhill Biopharma Inc.Movantik$93$7,60512 claims
Ferring Pharmaceuticals Inc.Clenpiq$210$3,37820 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →